Chief Operating Officer · Aura Biosciences, Inc. (AURA)

Mark De Rosch

FY2022 is the first fiscal year CompBrief holds for Mark De Rosch as a named executive officer of Aura Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$592,500

Salary $435,000Stock awards $0

2nd of 3 named executive officers at Aura Biosciences by FY2022 total.

3 named officers on file for Aura Biosciences, FY2022

Mark De Rosch’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aura Biosciences’s whole pay program stands against its peers

  • Aura Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AURA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2023 (DEF 14A).

Free

Get Mark De Rosch’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Mark De Rosch compensation by year

Aura Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Aura Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$435,000
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$139,200
Pension and deferred compensation$0
All other$18,300
Total$592,500

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aura Biosciences, Inc. DEF 14A filed April 25, 2023, accession 0001193125-23-115288, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aura Biosciences, Inc. filed document, accession 0001193125-23-115288. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,125$137,813—
Option78,461—$5.48
Option31,846—$5.48
Option53,125—$14.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Aura Biosciences, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Aura Biosciences’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Elisabet PinosPresident, Chief Executive Officer and Director$795,300
Mark De Rosch · this pageChief Operating Officer$592,500
Cadmus RichChief Medical Officer$581,500

The full Aura Biosciences compensation record

free company brief

This page is one person within Aura Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aura Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark De Rosch's compensation dossier · One-time report. No refunds.